Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 11/20 | 1.00 |
| ▸ | MAOB | P27338 | 11/20 | 1.00 |
| ▸ | TLR4 | O00206 | 9/20 | 1.00 |
| ▸ | TLR2 | O60603 | 9/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.64 |
| ▸ | CDK1 | P06493 | 1/20 | 0.64 |
| ▸ | CDK4 | P11802 | 1/20 | 0.64 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.64 |
| ▸ | CCND1 | P24385 | 1/20 | 0.64 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.64 |
| ▸ | LCK | P06239 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL510223 | 1.00 | MAOA (1.00) | MAOAMAOBTLR4TLR2CCNB2 | |
| SCHEMBL5720900 | 0.90 | TLR4 (0.81) | MAOAMAOBTLR4TLR2LCK | |
| SCHEMBL5720904 | 0.90 | TLR4 (0.81) | MAOAMAOBTLR4TLR2LCK | |
| SCHEMBL509861 | 0.84 | MAOA (0.72) | MAOAMAOBTLR4TLR2LCK | |
| SCHEMBL509860 | 0.84 | MAOA (0.72) | MAOAMAOBTLR4TLR2LCK | |
| SCHEMBL236394 | 0.84 | MAOA (0.72) | MAOAMAOBTLR4TLR2LCK | |
| SCHEMBL236393 | 0.84 | MAOA (0.72) | MAOAMAOBTLR4TLR2LCK | |
| SCHEMBL3235707 | 0.83 | MAOA (0.70) | MAOAMAOBTLR4TLR2 | |
| SCHEMBL3235702 | 0.83 | MAOA (0.70) | MAOAMAOBTLR4TLR2 | |
| SCHEMBL3657658 | 0.82 | TLR4 (0.69) | MAOAMAOBTLR4TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841327-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| EP-1944303-B1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROCYCLE AND FUNGICIDE CONTAINING THE SAME | EISAI R&D MAN CO LTD (JP) | 2013-08-21 | — | — | EP | disclosed |
| US-8507530-B2 | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8507530-B2 | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| CN-101300250-B | Heterocyclic substituted pyridine derivative and antifungal agent containing the same | EISAI R&D MAN CO LTD | 2012-09-05 | — | — | CN | disclosed |
| US-8158657-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-8158657-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-8153662-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153662-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20120029023-A1 | HETEROCYCLES SUBSTITUTED PYRIDINE DERIVATIVES AND ANTIFUNGAL AGENT CONTAINING THEREOF | TANAKA KEIGO (JP) | 2012-02-02 | — | — | US | disclosed |
| US-7259183-B2 | Indole, indazole and indoline derivatives as CETP inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| CN-1993323-A | Indole, indazole or indoline derivatives | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | CN | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1776338-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2006013048-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | disclosed |
| US-20040157859-A1 | Pyrrolidones with anti-HIV activity | IRM LLC, A DELAWARE LLC (BM) | 2004-08-12 | — | — | US | disclosed |
| WO-2004037784-A2 | PYRROLIDONES WITH ANTI-HIV ACTIVITY | IRM LLC (BM) | 2004-05-06 | — | — | WO | disclosed |
| WO-2001055117-A1 | NOVEL ISOQUINOLINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | CETP, NAT1, MTTP | MAOA 227/4885MAOB 147/4885TLR4 3193/4885 |
| US-20040157859-A1 | Pyrrolidones with anti-HIV activity | PREP, DHPS, PDCD11 | MAOA 3611/4885MAOB 3507/4885TLR4 3805/4885 |
| US-20120029023-A1 | HETEROCYCLES SUBSTITUTED PYRIDINE DERIVATIVES AND ANTIFUNGAL AGENT CONTAINING THEREOF | CYP4X1, ERG28, CYP51A1 | MAOA 596/4885MAOB 568/4885TLR4 1939/4885 |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | GPI, ERG28, MAN2A1 | MAOA 940/4885MAOB 690/4885TLR4 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.